Generate Biomedicines, Inc.
GENB Nasdaq
SEC CIK 2100782
Follow Generate Biomedicines
Weekly email: filings, results
Revenue, last quarter
$4.2M
−56.2% vs same quarter last year
Net income
−$87.7M
−63.5% vs same quarter last year
EPS, diluted
−$0.68
+65.5% vs same quarter last year
Operating cash flow
−$54.9M
−13.3% vs same quarter last year
Source: SEC XBRL filings · latest filing